A severe case of bevacizumab-induced thrombotic microangiopathy.
Clicks: 214
ID: 51736
2019
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
2.7
/100
9 views
9 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Bevacizumab is a human monoclonal antibody against VEGF. Many adverse reactions about bevacizumab are identified including venous and arterial thromboembolism, nausea, fatigue, alopecia, proteinuria, gastrointestinal system (GIS) perforation, exfoliative dermatitis, and peripheral edema and thrombocytopenia. In this paper, we report a case of bevacizumab-induced dose-dependent, toxicity-mediated drug-induced thrombotic microangiopathy.
| Reference Key |
bektas2019ajournal
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Bektas, Mert;Samancı, Nilay S;Cokgezer, Simay;Keskin, Dilek;Demirelli, Fuat H; |
| Journal | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners |
| Year | 2019 |
| DOI |
10.1177/1078155218800371
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.